- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | EU approves Otsuka's long-acting HAE drug Dawnzera | ||
| Mi | Hopstem maps course to bring stem cell stroke therapy to US | ||
| Mi | ImmunityBio rises as route opens to broader Anktiva label | ||
| Mi | Call goes out for type 1 diabetes screening in UK | ||
| Mi | Data builds behind Moderna's skin cancer vaccine | ||
| Di | J&J bets on Isomorphic for AI-powered drug hunt | ||
| Di | ViiV ownership shifts as Pfizer sells its stake | ||
| Di | Agomab and Spyglass push the IPO button | ||
| Di | AstraZeneca pays $630m to get full control of AbelZeta CAR-T | ||
| Di | GSK reaches $2.2bn deal to buy food allergy biotech RAPT | ||
| Mo | Sun Pharma says talk of $10bn Organon bid is 'speculative' | ||
| Mo | EU starts review of first-line Enhertu for breast cancer | ||
| Mo | Could Alzheimer's be predicted with a finger-prick test? | ||
| Mo | NICE relents, ending postcode access to prostate cancer drug | ||
| Mo | 'Skinny' generic Vascepa label case reaches US Supreme Court | ||
| Fr | Wegovy pill shows strong early uptake, as rival looms | ||
| Fr | Sanofi linked to takeover bid for Ocular Therapeutix | ||
| Fr | Ocugen shares fall, despite positive eye disorder trial | ||
| Fr | Autonomous AI can spot cognitive decline in medical notes | ||
| Fr | Trump's affordability plan arrives, built around MFN pricing | ||
| 15.01. | J&J builds case for earlier Tecvayli use in multiple myeloma | ||
| 15.01. | Novartis issues a life sciences warning in a 'G-Zero' world | ||
| 15.01. | Novo Nordisk Foundation pledges €736m for European biotech | ||
| 15.01. | EMA and FDA agree 'principles' for AI in drug development | ||
| 15.01. | Oxford BioMedica confirms private equity takeover talks |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .